AU2002234513A1 - Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes - Google Patents
Method of generating diversity into lipolytic enzymes and lipolytic enzyme genesInfo
- Publication number
- AU2002234513A1 AU2002234513A1 AU2002234513A AU2002234513A AU2002234513A1 AU 2002234513 A1 AU2002234513 A1 AU 2002234513A1 AU 2002234513 A AU2002234513 A AU 2002234513A AU 2002234513 A AU2002234513 A AU 2002234513A AU 2002234513 A1 AU2002234513 A1 AU 2002234513A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- mature peptide
- acid sequence
- identity
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000790 Enzymes Proteins 0.000 title claims description 66
- 102000004190 Enzymes Human genes 0.000 title claims description 57
- 230000002366 lipolytic effect Effects 0.000 title claims description 51
- 238000000034 method Methods 0.000 title claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 67
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 41
- 239000013612 plasmid Substances 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 25
- 108091033319 polynucleotide Proteins 0.000 claims description 25
- 102000040430 polynucleotide Human genes 0.000 claims description 25
- 239000002157 polynucleotide Substances 0.000 claims description 25
- 241000588724 Escherichia coli Species 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003599 detergent Substances 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 13
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 241001261109 Thermomyces ibadanensis Species 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 108020002496 Lysophospholipase Proteins 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 241000030452 Rasamsonia byssochlamydoides Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 235000013312 flour Nutrition 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 2
- 241000228341 Talaromyces Species 0.000 claims description 2
- 241000223257 Thermomyces Species 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 229940100445 wheat starch Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 125000001924 fatty-acyl group Chemical group 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 49
- 108020004414 DNA Proteins 0.000 description 34
- 239000012634 fragment Substances 0.000 description 32
- 102000004882 Lipase Human genes 0.000 description 28
- 239000004367 Lipase Substances 0.000 description 28
- 235000019421 lipase Nutrition 0.000 description 28
- 239000011543 agarose gel Substances 0.000 description 14
- 238000010367 cloning Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 241001136490 Thermomyces dupontii Species 0.000 description 9
- 108010019653 Pwo polymerase Proteins 0.000 description 7
- 241000959173 Rasamsonia emersonii Species 0.000 description 7
- 241000228212 Aspergillus Species 0.000 description 6
- 108091092195 Intron Proteins 0.000 description 6
- 239000012620 biological material Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 241000228245 Aspergillus niger Species 0.000 description 4
- 235000008429 bread Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 3
- 240000006439 Aspergillus oryzae Species 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- 241000223258 Thermomyces lanuginosus Species 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- 241000228232 Aspergillus tubingensis Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 101150050575 URA3 gene Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000004851 dishwashing Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 101150116440 pyrF gene Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- KDYAPQVYJXUQNY-OPHDRXFHSA-N 1,2-di-(alpha-linolenoyl)-3-[alpha-D-galactosyl-(1->6)-beta-D-galactosyl]-sn-glycerol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KDYAPQVYJXUQNY-OPHDRXFHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000892910 Aspergillus foetidus Species 0.000 description 1
- 241000122205 Chamaeleonidae Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100033357 Pancreatic lipase-related protein 2 Human genes 0.000 description 1
- 101000579646 Penaeus vannamei Penaeidin-1 Proteins 0.000 description 1
- 102100035200 Phospholipase A and acyltransferase 4 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 101001095983 Staphylococcus aureus Protein rep Proteins 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 101000984201 Thermomyces lanuginosus Lipase Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 101150102092 ccdB gene Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010061330 glucan 1,4-alpha-maltohydrolase Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009884 interesterification Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010072641 thermostable lipase Proteins 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- -1 tributyrine Chemical compound 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Description
LIPOLYTIC ENZYME GENES
FIELD OF THE INVENTION
The present invention relates to a method of generating diversity into lipolytic enzymes by the use of the so-called family shuffling of homologous genes. The invention also relates to polynucleotides for use in the method, and to lipolytic enzymes encoded by the polynucleotides.
BACKGROUND OF THE INVENTION
The lipase of Thermomyces lanuginosus (also known as Humicola lanuginosa) is known to be useful for various industrial purposes such as detergents and baking (EP 258068, WO 9404035). Its amino acid and DNA sequences are shown in US 5869438.
The prior art describes the modification of the amino acid sequence of the 7. lanuginosus lipase to create variants with the aim of modifying the enzyme properties. Thus, US 5869438, WO 9522615, WO 9704079 and WO 0032758 disclose the use of mutagenesis of the lipase gene to produce such variants. WO 0032758 also discloses the construction of variants with the backbone from 7. lanuginosus lipase and C-terminal from Fusarium oxysporum phos- pholipase by PCR reaction.
Crameri et al, 1998, Nature, 391 : 288-291 discloses DNA shuffling of a family of naturally occurring homologous genes from diverse species to create diversity into proteins. US 6159687 discloses shuffling of genes encoding variants of the 7. lanuginosus lipase. WO 9841623 discloses shuffling of heterologous polynucleotide sequences.
The following published sequences of lipolytic enzymes from Aspergillus have amino acid identities of 49-51 % to the 7. lanuginosus lipase: Lysophospholipase from A. foetidus
(EMBL A93428, US 6140094), lipase from A. tubingensis (EMBL A84589, WO 9845453), phospholipase A1 from A. oryzae (EMBL E16314, EP 575133, JP 10155493 A) and Lysophos- pholipase from A. niger (EMBL A90761 , WO 98/31790).
R. Lattmann et al., Biocatalysis, 3 (1-2), 137-144 (1990) disclose an esterase from 7a- laromyces thermophilus. V.W. Ogundero, Mycologia, 72 (1), 118-126 (1980) describes the lipase activity of Talaromyces thermophilus. US 4275011 and EP 258068 refer to a lipase from Thermomyces ibadanensis. B.A. Oso, Canadian Journal of Botany, 56: 1840-1843 (1978) de- scribes the lipase activity of Talaromyces emersonii.
SUMMARY OF THE INVENTION
The inventors have isolated novel lipolytic enzyme genes with a high homology to the 7. lanuginosus lipase gene and are thus well suited for use in gene shuffling. The novel genes are shown as SEQ ID NO: 3, 5, 7, 9 and 11. Identity tables for some protein and DNA se- quences are shown below. The novel sequences are identified as follows:
• Talthel M: SEQ ID NO: 3 and 4 from Talaromyces thermophilus.
• Theibal M: SEQ ID NO: 5 and 6 from Thermomyces ibadanensis.
• TalemelM: SEQ ID NO: 7 and 8 from Talaromyces emersonii.
• TalbyslM: SEQ ID NO: 9 and 10 from Talaromyces byssochlamydoides. The following known sequences are included for comparison:
• ThelanlM: Lipase from Thermomyces lanuginosus, SEQ ID NO: 1 and 2.
• Asptub2M: EMBL A84589 Lipase from Aspergillus tubingensis.
• Aspory3M: EMBL E16314 Phospholipase A1 from Aspergillus oryzae.
• Aspnig2M: EMBL A90761 Lysophospholipase from Aspergillus niger. The following is an identity table of the mature proteins:
The following is an identity table of DNA sequences coding for the mature proteins (stop codons omitted):
Accordingly, the invention provides a method of generating genetic diversity into lipolytic enzymes by family shuffling of two or more homologous genes which encode lipolytic enzymes. One gene encodes a lipolytic enzyme with at least 90 % identity to the 7. lanugino- sus lipase, and another gene encodes a lipolytic enzyme with 55-90 % identity to the 7. lanuginosus lipase. The DNA shuffling technique is used to create a library of chimeric shuffled genes, and this is expressed in a suitable expression system and the expressed proteins are screened for lipolytic enzyme activity. The expressed proteins may further be screened to identify lipolytic enzymes with improved properties. The invention also provides a polynucleotide comprising a nucleotide sequence encoding a lipolytic enzyme and a lipolytic enzyme (a polypeptide with lipolytic enzyme activity).
The polynucleotide may be a DNA sequence cloned into a plasmid present in E. coli deposit number DSM 14047, 14048, 14049, or 14051 , the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9 or one that can be derived therefrom by substitution, deletion, and/or insertion of one or more nucleotides. The polynucleotide may have at least 90 % identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, at least 80 % identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 5, at least 65 % identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 7, or at least 60 % identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 9. It may also be an allelic variant of the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9; or it may hybridize under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
The lipolytic enzyme may be encoded by a DNA sequence cloned into a plasmid pre- sent in E. coli deposit number DSM 14047 or 14049, or may have an amino acid sequence which is the mature peptide of SEQ ID NO: 6 or 10, or one that can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids. The lipolytic enzyme may have an amino acid sequence which has at least 80 % identity with the mature peptide of SEQ ID NO: 6 or at least 60 % identity with the mature peptide of SEQ ID NO: 10. The lipolytic en- zyme may further be immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 6 or 10 in purified form, be an allelic variant of the mature peptide of SEQ ID NO: 6 or 10; or be encoded by a nucleic acid sequence which hybridizes under high strin-
gency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 5 or 9, or a subsequence thereof having at least 100 nucleotides.
BRIEF DESCRIPTION OF DRAWINGS
Fig. 1 shows a PCR scheme used in Example 7.
5 DETAILED DESCRIPTION OF THE INVENTION
Genomic DNA source
Lipolytic enzyme genes of the invention may be derived from strains of Talaromyces or Thermomyces, particularly Talaromyces thermophilus, Thermomyces ibadanensis, Talaromyces emersonii or Talaromyces byssochlamydoides, using probes designed on the basis of the 10 DNA sequences in this specification.
Thus, genes and polypeptides shown in the sequence listing were isolated from the organisms indicated below. Strains of Escherichia coli containing the genes were deposited by the inventors under the terms of the Budapest Treaty with the DSMZ - Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig
15 DE as follows:
The above source organisms are freely available on commercial terms from the following strain collections:
ATCC (American Type Culture Collection), 10801 University Boulevard, Manassas, VA 20 20110-2209, USA.
CBS (Centraalbureau voor Schimmelcultures), Uppsalalaan 8, 3584 CT Utrecht, The Netherlands.
UAMH (University of Alberta Mold Herbarium & Culture Collection), Devonian Botanic Garden, Edmonton, Alberta, Canada T6G 3GI.
IMI: International Mycological Institute, Bakeham Lane, Englefield Green, EGHAM, Surrey TW20 9TY, United Kingdom.
Polynucleotides
The polynucleotides to be used for recombination (shuffling) are two or more genes encoding lipolytic enzymes, including one with at least 90 % identity and one with 55-90 % identity to the 7. lanuginosus lipase (SEQ ID NO: 2). The poloynucleotides differ in at least one nucleotide. The starting material may include the mature part of two or more (e.g. three, four or five) of SEQ ID NO: 1 , 3, 5, 7 and/or 9. It may also include genes encoding two or more (e.g. three, four or five) of variants of SEQ ID NO: 2, 4, 6, 8 or 10 obtained by deleting, substituting and/or inserting one or more amino acids and/or by attaching a peptide extension at the N- and/or C-terminal. Examples of variants of the 7. lanuginosus lipase are described, e.g., in US 5869438, WO 9522615, WO 9704079 and WO 0032758, and similar variants can be made by altering corresponding amino acids in the other sequences.
Any introns present in the genes may optionally be removed before the shuffling.
DNA recombination (shuffling)
Shuffling between two or more homologous input polynucleotides (starting-point polynucleotides) may involve fragmenting the polynucleotides and recombining the fragments, to obtain output polynucleotides (i.e. polynucleotides that have been subjected to a shuffling cycle) wherein a number of nucleotide fragments are exchanged in comparison to the input polynucleotides.
DNA recombination or shuffling may be a (partially) random process in which a library of chimeric genes is generated from two or more starting genes. A number of known formats can be used to carry out this shuffling or recombination process.
The process may involve random fragmentation of parental DNA followed by reassembly by PCR to new full length genes, e.g. as presented in US5605793, US5811238, US5830721 , US6117679 . In-vitro recombination of genes may be carried out, e.g. as de- scribed in US6159687, WO98/41623, US6159688, US5965408, US6153510. The recombination process may take place in vivo in a living cell, e.g. as described in WO 97/07205 and WO 98/28416.
The parental DNA may be fragmented by DNA'se I treatment or by restriction endonu- clease digests as descriobed by Kikuchi et al (2000a , Gene 236:159-167). Shuffling of two parents may be done by shuffling single stranded parental DNA of the two parents as described in Kikuchi et al (2000b , Gene 243:133-137). A particular method of shuffling is to follow the methods described in Crameri et al,
1998, Nature, 391: 288-291 and Ness et al. Nature Biotechnology 17: 893-896. Another format would be the methods described in US 6159687: example 1 and 2.
Properties of lipolytic enzyme
The lipolytic enzyme obtained by the invention is able to hydrolyze carboxylic ester bonds and is classified as EC 3.1.1 according to Enzyme Nomenclature 1992, Academic Press, Inc. It may particularly have activity as a lipase (triacylglycerol lipase) (EC 3.1.1.3), phospholipase A1 (EC 3.1.1.32), phospholipase A2 (EC 3.1.1.4), cholesterol esterase (EC 3.1.1.13) and/or galactolipase (EC 3.1.1.26).
The thermostability was evaluated by means of Differential Scanning Calorimetry (DSC). The denaturation peak (Td) when heated at 90 deg/hr at pH 5 is slightly above 75°C for the lipolytic enzyme from 7. ibadanensis, compared to slightly above 70 °C for the prior-art 7. lanuginosus lipase. The lipolytic enzyme from 7. ibadanensis has optimum activity at alkaline pH (similar to the 7. lanuginosus lipase) and has an isoelectric point of about 4.3 (slightly lower than the 7. lanuginosus lipase).
Homology and alignment
The best alignment of the mature parts of SEQ ID NO: 2, 4, 6, 8 and 10 is achieved by inserting a gap of one amino acid between Q249 and P/G250 of SEQ ID NO: 2, 4 and 6. This alignment defines corresponding amino acids.
The degree of homology may be determined by means of computer programs known in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, CD., (1970), Journal of Molecular Biology, 48, 443-45), using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1. The determination of homology may also be made using Align from the fasta package version v20u6. Align is a Needleman-Wunsch alignment (i.e. global alignment), useful for both protein and DNA alignments. The default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively. The penalty for the first residue in a gap
is -12 for proteins and -16 for DNA. While the penalty for additional residues in a gap is -2 for proteins and -4 for DNA.
The homologies discussed in this specification may correspond to at least 60 % identity, in particular to at least 70 % or at least 80 % identity, e.g. at least 90 % or at least 95 % identity.
Use of lipolytic enzyme
Depending on the substrate specificity, the enzyme of the invention can be used, e.g., in filtration improvement, vegetable oil treatment, baking, detergents, or preparation of lyso- phospholipid. Thus, it may be used in known applications of lipolytic enzymes by analogy with the prior art, e.g.:
• In the pulp and paper industry, to remove pitch or to remove ink from used paper. WO 9213130, WO 9207138, JP 2160984 A, EP 374700.
• Baking. WO 94/04035, WO 00/32758.
• Detergents. WO 97/04079, WO 97/07202, WO 97/41212, WO 98/08939 and WO 97/43375.
• Leather industry. GB 2233665, EP 505920.
• An enzyme with lipase activity may be used for fat hydrolysis and for modification of triglycerides and for production of mono- and diglycerides.
• An enzyme with lipase activity may be used for interesterification of bulk fats, pro- duction of frying fats, shortenings and margarine components.
• An enzyme with phospholipase activity (A1 , A2) may be used for degumming of vegetable oils and for lysophospholipid production.
Improvement of filtration
An enzyme with lysophospholipase activity can be used to improve the filterability of an aqueous solution or slurry of carbohydrate origin by treating it with the variant. This is particularly applicable to a solution or slurry containing a starch hydrolysate, especially a wheat starch hydrolysate since this tends to be difficult to filter and to give cloudy filtrates. The treatment can be done in analogy with EP 219,269 (CPC International).
Detergents The lipolytic enzyme produced by the invention may be used as a detergent additive, e.g. at a concentration (expressed as pure enzyme protein) of 0.001-10 (e.g. 0.01-1) mg per gram of detergent or 0.001-100 (e.g. 0.01-10) mg per liter of wash liquor.
The detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations. In a laundry detergent, the variant may be effective for the removal of fatty stains, for whiteness maintenance and for dingy cleanup. A laundry detergent composition may be formulated as described in WO 97/04079, WO 97/07202, WO 97/41212, PCT/DK WO 98/08939 and WO 97/43375.
The detergent composition of the invention may particularly be formulated for hand or machine dishwashing operations, e.g. as described in GB 2,247,025 (Unilever) or WO 99/01531 (Procter & Gamble). In a dishwashing composition, the variant may be effective for removal of greasy/oily stains, for prevention of the staining /discoloration of the dishware and plastic components of the dishwasher by highly colored components and the avoidance of lime soap deposits on the dishware. The detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may be aqueous, typically containing up to 70 % water and 0-30 % organic solvent, or non-aqueous.
The detergent composition comprises one or more surfactants, which may be non- ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight, e.g. 0.5-40 %, such as 1-30 %, typically 1.5-20 %.
Dough and baked products
The lipolytic enzyme can be used in the preparation of dough and baked products made from dough, such as bread and cakes, e.g. to increase dough stability and dough han- dling properties, or to improve the elasticity of the bread or cake. Thus, it can be used in a process for making bread, comprising adding it to the ingredients of a dough, kneading the dough and baking the dough to make the bread. This can be done in analogy with US 4,567,046 (Kyowa Hakko), JP-A 60-78529 (QP Corp.), JP-A 62-111629 (QP Corp.), JP-A 63-258528 (QP Corp.) or EP 426211 (Unilever). The lipolytic enzyme may be used together with an anti-staling amylase, particularly an endo-amylase such as a maltogenic amylase in analogy with WO 99/53769 (Novo Nordisk). Thus, the lipolytic enzyme may be incorporated in a flour composition such as a dough or a premix for dough.
MATERIALS AND METHODS
Strains and plasmids:
Plasmid pMT2188
The Aspergillus oryzae expression plasmid pCaHj 483 (WO 98/00529) consists of an
5 expression cassette based on the Aspergillus niger neutral amylase II promoter fused to the Aspergillus nidulans triose phosphate isomerase non translated leader sequence (Pna2/tpi) and the A. niger amyloglycosidase terminator (Tamg). Also present on the plasmid is the Aspergillus selective marker amdS from A. nidulans enabling growth on acetamide as sole nitrogen source. These elements are cloned into the E. coli vector pUC19 (New England Biolabs). 10 The ampicillin resistance marker enabling selection in E. coli of this plasmid was replaced with the URA3 marker of Saccharomyces cerevisiae that can complement a pyrF mutation in E. coli, the replacement was done in the following way:
The pUC19 origin of replication was PCR amplified from pCaHj483 with the primers 142779 (SEQ ID NO: 35) and 142780 (SEQ ID NO: 36). 15 Primer 142780 introduces a Bbu\ site in the PCR fragment. The Expand PCR system
(Roche Molecular Biochemicals, Basel, Switserland) was used for the amplification following the manufacturers instructions for this and the subsequent PCR amplifications.
The URA3 gene was amplified from the general S. cerevisiae cloning vector pYES2 (Invitrogen corporation, Carlsbad, Ca, USA) using the primers 140288 (SEQ ID NO: 37) and 20 142778 (SEQ ID NO: 38).
Primer 140288 introduces an EcoRI site in the PCR fragment. The two PCR fragments were fused by mixing them and amplifying using the primers 142780 and 140288 in the splicing by overlap method (Horton et al (1989) Gene, 77, 61-68).
The resulting fragment was digested with EcoRI and Bbu\ and ligated to the largest 25 fragment of pCaHj 483 digested with the same enzymes. The ligation mixture was used to transform the pyrF E.coli strain DB6507 (ATCC 35673) made competent by the method of Mandel and Higa (Mandel, M. and A. Higa (1970) J. Mol. Biol. 45, 154). Transformants were selected on solid M9 medium (Sambrook et. al (1989) Molecular cloning, a laboratory manual, 2. edition, Cold Spring Harbor Laboratory Press) supplemented with 1 g/l casaminoacids, 500 30 μg/l thiamine and 10 mg/l kanamycin.
A plasmid from a selected transformant was termed pCaHj 527. ThePna2/tpi promoter present on pCaHj527 was subjected to site directed mutagenises by a simple PCR approach.
Nucleotide 134 - 144 was altered from SEQ ID NO: 39 to SEQ ID NO: 40 using the mutagenic primer 141223 (SEQ ID NO: 41).
Nucleotide 423 - 436 was altered from SEQ ID NO: 42 to SEQ ID NO: 43 using the mutagenic primer 141222 (SEQ ID 44).
The resulting plasmid was termed pMT2188.
Plasmid pENH 861 Plasmid pENI1861 was made in order to have the state of the art Aspergillus promoter in the expression plasmid, as well as a number of unique restriction sites for cloning.
A PCR fragment (app. 620 bp) was made using pMT2188 (see above) as template and the primers 051199J1 (SEQ ID 45) and 1298TAKA (SEQ ID 46).
The fragment was cut BssHII and Bgl II, and cloned into pENI1849 which was also cut with BssHII and Bgl II. The cloning was verified by sequencing. Plasmid pENI1902 was made in order to have a promoter that works in both E.coli and Aspergillus. This was done by unique site elimination using the "Chameleon double stranded site-directed mutagenesis kit" as recommended by Stratagene®.
Plasmid PENI1861 Plasmid pENI1861 was used as template and the following primers with 5' phosphory- lation were used as selection primers: 177996 (SEQ ID 47), 135640 (SEQ ID 48) and 135638
(SEQ ID 49).
The 080399J19 primer (SEQ ID NO: 50) with 5 phosphorylation was used as mutagenic primer to introduce a -35 and -10 promoter consensus sequence (from E.coli) in the Aspergillus expression promoter. Introduction of the mutations was verified by sequencing.
Plasmid pENH 960
Plasmid pENI1960 was made using the Gateway Vector™ conversion system
(Lifetechnology® cat no. 11828-019) by cutting pENI1902 with BamHI, filling the DNA ends using Klenow fragment polymerase and nucleotides (thus making blunt ends) followed by ligation to reading frame A Gateway™ PCR fragment. The cloning in the correct orientation was confirmed by sequencing.
Media and substrates
YPG: 4 g/L Yeast extract, 1 g/L KH2PO4, 0.5 g/L MgSO4-7aq, 5 g/L Glucose, pH 6.0.
EXAMPLES
Example 1 : Plasmids harboring lipolytic enzyme genes
Genomic DNA preparation
Strains of Thermomyces ibadanensis, Talaromyces emersonii, Talaromyces bys- sochlamydoides, and Talaromyces thermophilus were used as a genomic DNA supplier. Each strain was cultivated in 100 ml of YPG at appropriate temperature for several days. Mycelia was harvested and ground in liquid N2. It was suspended with 2 ml of 50 mM Tris-HCI (pH8.0) buffer including 100 mM NaCl, 25 mM EDTA, and 1% SDS and then 12μl of proteinase K (25 mg/ml) was added. The suspension was incubated at 65° C for 30~60min. Phenol extraction was done to remove proteins and DNA was precipitated by 0J volume of isopropanol. The precipitate was dissolved with sterilized water and RNase was added. After Phenol / isoamylalco- hol extraction, DNA was precipitated by EtOH.
PCR screening of lipolytic enzyme genes
PCR reactions on each genomic DNA was done with HL 2 and HL12 (SEQ ID NO: 51 and 52) or HL2 and HL6 (SEQ ID NO: 51 and 53) designed based upon alignment lipases.
Reaction components (2.6 ng /μl of genomic DNA, 250 mM dNTP each, primer 250 nM each, 0.1 U/ μl of Taq polymerase in 1X buffer (Roche Diagnostics, Japan)) were mixed and submitted for PCR under the following conditions.
Steps 1 to 3 were repeated 30 times.
540 bp of fragment and 380 bp of fragment were amplified from primer sets of HL2/HL12 and HL2/HL6, respectively. They were gel-purified with GFX™ PCR DNA and Gel Band Purification kit (amersham pharmacia biotech) Each DNA was sequenced and compared to the lipase, showing that a clone encodes the internal part of the lipase.
Cloning of lipase genes
All lipase genes were cloned using LA PCR™ in vitro Cloning Kit (TaKaRa) according to the manufacturer's instructions. Thus, genomic DNA was cut with various restriction enzymes and each DNA was ligated with the appropriate cassette of the kit. Each ligation solution was applied to PCR with the primers of the one designed from internal sequence and a cassette primer of the kit. Amplified DAN fragment was sequenced. This step was repeated till ORF was determined.
The fidelity of LA- taq polymerase of the kit is not good so in order to get the right sequence whole gene was amplified by Expand high fidelity polymerase according to the manu- facturer's instructions.
Amplified DNA fragment was gel-purified with GFX™ PCR DNA and Gel Band Purification kit (Amersham Pharmacia Biotech) and ligated into a pT7Blue vector or pST BLue -1 AccepTor vector (Novagen) with ligation high (TOYOBO, Japan) . The ligation mixtures were transformed into E. coli JM109 or DH5α. The sequence of four plasmids of each gene was de- termined and their sequence were compared. The sequence of majority is defined as the right nucleotide sequence.
Example 2: Cloning of lipase into Aspergillus expression vector.
3 different PCR reaction were run using PWO polymerase in the following reaction 94°C 5 min, 30* (94°C 30 sec, 50°C 30 sec, 72°C 2 min), 72°C 5min). In each case, the tem- plate was a plasmid harboring a lipolytic enzyme gene prepared as in Example 1 , and the following primers were used:
A: Plasmid with gene from Talaromyces thermophilus and oligo 051200J1 /051200J8 (SEQ ID NO: 11 and 18).
B: Plasmid with gene from Talaromyces emersonii and oligo 051200J9 /051200J16 (SEQ ID NO: 19 and 26).
C: Plasmid with gene from Thermomyces Ibadanensis and oligo 051200J17/051200J24 (SEQ ID NO: 27 and 34).
The PCR fragments were run and purified from a 1% agarose gel and cloned into pENI1960 (see above) using Gateway cloning as recommended by the supplier (Life Tech- nologies) and transformed into E.coli DH10b (Life Technologies, Gaithersburg, MD) and sequenced, thus creating pENI 2146 (Talaromyces emersonii lipase genej, pENI2147 (Thermomyces Ibadanensis lipase gene) and pENI2148 (Talaromyces thermophilus lipase gene).
These were transformed into Jal250 (described in WO 00/39322) and lipase activity identified as mentioned in pat WO 00/24883.
Example 3: Construction of intron-less lipase genes
Removal of introns from Talaromyces thermophilus lipase gene
4 PCR reactions were run using PWO polymerase and pENI2148 as template (94°C 5 min, 30* (94°C 30 sec, 50°C 30 sec, 72°C 1 min), 72°C 5min) and the following oligoes: 1 : 051200J1 and 051200J3 (SEQ ID NO: 11 and 13)
2: 051200J2 and 051200J5 (SEQ ID NO: 12 and 15)
3: 051200J4 and 051200J7 (SEQ ID NO: 14 and 17)
4: 051200J6 and 051200J8 (SEQ ID NO: 16 and 18)
The specific bands were run and purified from a 1.5 % agarose gel. Equal amounts of PCR fragments were mixed along with PWO polymerase, buffer, dNTP, oligo 051200J1 and
051200J8 (SEQ ID NO: 11 and 18, total of 50 μl, as recommended by the supplier Boehringer
Mannheim) and a second PCR was run (94°C 5 min, 30* (94°C 30 sec, 50°C 30 sec, 72°C 2 min), 72°C 5min).
The correct band size was checked on a 1.5 % agarose gel ( app. 900 bp) and the rest of the PCR-fragment was purified using Biorad spin columns (cat no.732-6225)
The PCR-fragment was cloned into pENI1960 cut with Seal (in order to cleave in the ccdB gene) using Gateway cloning as recommended by the supplier (Life Technologies) and transformed into E. coli DH10b and sequenced, thus creating intron-less Talaromyces thermophilus lipase gene.
Removal of introns from Talaromyces emersonii lipase gene
4 PCR reactions were run using PWO polymerase and pENI2146 as template (94°C 5 min, 30* (94°C 30 sec, 50°C 30 sec, 72°C 1 min), 72°C 5min) and the following oligoes:
1 : 051200j9 and 051200j11 (SEQ ID NO: 19 and 21).
2: 051200J10 and 051200J13 (SEQ ID NO: 20 and 23). 3: 051200J12 and 051200J15 (SEQ ID NO: 22 and 25).
4: 051200J14 and 051200J16 (SEQ ID NO: 24 and 26).
The specific bands were run and purified from a 1.5 % agarose gel. Equal amounts of PCR fragments were mixed along with PWO polymerase, buffer, dNTP, oligo 051200J9 and 051200J16 (SEQ ID NO: 19 and 26, total of 50 μl, as recommended by the supplier) and a sec- ond PCR was run (94°C 5 min, 30* (94°C 30 sec, 50°C 30 sec, 72°C 2 min), 72°C 5min).
The correct band size was checked on a 1.5 % agarose gel (app. 900 bp) and the rest of the PCR-fragment was purified using Biorad spin columns.
The PCR-fragment was cloned into and cloned into pENI1960 cut Seal using Gateway cloning as recommended by the supplier (Life Technologies) and transformed into E.coli DH10b and sequenced, thus creating an intron-less Ta/aromyces emersonii lipase gene.
Removal of introns from Thermomyces Ibadanensis lipase gene 4 PCR reactions were run using PWO polymerase and pENI2147 as template (94°C 5 min, 30* (94°C 30 sec, 50°C 30 sec, 72°C 1 min), 72°C 5min) and the following oligoes:
1 : 051200J17 and 051200J19 (SEQ ID NO: 27 and 29).
2: 051200J18 and 051200J21 (SEQ ID NO: 28 and 31).
3: 051200J20 and 051200J23 (SEQ ID NO: 30 and 33). 4: 051200J22 and 051200J24 (SEQ ID NO: 32 and 34).
The specific bands were run and purified from a 1.5 % agarose gel. Equal amounts of PCR fragments were mixed along with PWO polymerase, buffer, dNTP, oligo 051200J17 and 051200J24 (SEQ ID NO: 27 and 34, total of 50 μl, as recommended by the supplier) and a second PCR was run (94°C 5 min, 30* (94°C 30 sec, 50°C 30 sec, 72°C 2 min), 72°C 5min). The correct band size was checked on a 1.5 % agarose gel ( app. 900 bp) and the rest of the PCR-fragment was purified using Biorad spin columns
The PCR-fragment was cloned into and cloned into pENI1960 cut Seal using Gateway cloning as recommended by supplier (life technologies) and transformed into E.coli DH10b and sequenced, thus creating intron-less Thermomyces Ibadanensis lipase gene.
Example 4: Shuffling of lipolytic enzyme genes
Plasmids containing DNA sequences encoding lipolytic enzymes are mixed in equimo- lar amounts. The following components where mixed in a microtube:
2 μl plasmid mixture (0.15 μg/μl), specific primers flanking the gene (1 pmol/μ), 2 μl 2.5 mM dNTP, 2.5 mM MgCI2, 2 μl 10* taq buffer (Perkin Elmer), 0.5 μl taq enzyme in a total vol- ume of 20 μl.
The tube is set in a Perkin Elmer 2400 thermocycler. The following PCR-program is run:(94°C, 5 minutes) 1 cycle:
(94°C , 30 seconds, 70°C, 0 seconds) 99 cycles(72°C, 2 minutes, 4°C indefinite) 1 cycle The PCR-reaction is run on a 1.5 % agarose gel. A DNA-band of the specific expected size is cut out of the agarose gel and purified using JETsorb (from GENOMED Inc.). The purified PCR-product is cloned into a TA-vector (from Invitrogen (the original TA cloning kit). The ligated product is transformed into a standard Escherichia coli strain (DH5a).
The shuffled sequences can then be subcloned from the E. coli TA vector into the yeast vector pJS0026 (WO 9928448) as a BamHI-Xbal fragment (see WO 97/07205), and e.g. screened for new shuffled sequences with improved properties, e.g. improved performance in detergents (see WO 97/07205).
Example 5: Shuffling of lipolytic enzyme genes
PCR products of lipolytic enzyme genes are generated as in the previous example and pooled in equimolar amounts. The following mixture is generated in a suitable tube:
1 μl PCR mixture (0.1 μg), decamer random primer (300 pmol), 2 μl 10* Klenow buffer (Promega), 0.25 mM dNTP, 2.5 mM MgCI2 in a total volume of 20 μl. The mixture is set in a PE2400 thermocycler where the following program is run: 96°C,
5 minutes, 25°C 5 minutes, 0.5 ml Klenow enzyme is added, 25°C 60 minutes, 35°C 90 minutes.
This procedure generates a high number of small DNA polymers originating from all parts of the gene 10 μl is taken out for test on agarose gel.
10 μl PCR mixture (0.25 mM dNTP, 1 μl 10* Taq buffer (Perkin Elmer), 2.5 mM MgCI2, 0.5 μl Taq enzyme) is added to the 10 μl in the tube in the thermocycler. Then the following standard PCR-program is run: (94°C, 5 minutes) 1 cycle, (94°C 30 seconds, 45°C, 30 seconds, 72°C 30 seconds) 25 cycles, 72°C 7 minutes, 4°C indefinite. The PCR products are run on a 1.5% agarose gel. A clear unbiased smear is seen.
DNA between 400 and 800 bp is isolated from the gel.
Half of the purified PCR product is mixed in a tube with two specific primers (40 pmol) flanking the gene of interest, 0.25 mM dNTP, 2 μl 10* Taq buffer, 2.5 mM MgCI2. Then the following standard PCR-program is run: (94°C , 5 minutes) 1 cycle, (94°C 30 seconds, 50°C, 30 seconds, 72°C 30 seconds) 25 cycles, 72°C 7 minutes, 4°C indefinite.
The PCR product is run on a 1.5% agarose gel. A band of the expected size is isolated. Additional PCR is run using specific primers (as mentioned above) in order to amplify the PCR-product before cloning.
The PCR-product and the desired vector are cut with the appropriate restriction en- zymes (BamHI/Xhol). The vector and the PCR product are run on a 1.5% agarose gel, and purified from the gel.
The cut PCR-product and the cut vector are mixed in a ligase buffer with T4 DNA li- gase (Promega). After overnight ligation at 16°C the mixture is transformed into E. coli strain DH5a.
Example 6: Creation of intron-less lipase genes
A number of lipase genes with homology to the Thermomyces lanuginosus lipase gene were cloned. These genes were cloned as genomic DNA and were thus known to contain introns. The intention was to shuffle these genes in order to obtain chimeric genes. In order to obtain the highest possible quality of library, the introns had to be removed. This was done by creating DNA oligo's matching each flank of an exon as well as having a DNA sequence, which is homologous to the next neighbour exon.
These oligoes were used in standard PCR (as known to a person skilled in the art), thus creating PCR fragments covering each and every exon (coding sequence) in the gene. These PCR fragments were purified from a 1 % agarose gel. The PCR fragments were assembled into a full length gene, in a second PCR using the DNA oligoes flanking the whole gene, as primers.
The PCR fragment containing the full length intron-less gene encoding the lipase was cloned into pEN1 1960 as described in pat. appl. PCT/DK02/00050.
The following primers were used to assemble each intron-less gene: Talaromyces thermophilus: 051200 1 , 051200J2, 051200J3, 051200J4, 051200J5, 051200J6, 051200J7 and 051200J8 (SEQ ID NO: 11-18), thus creating pENI2178, when cloned into pEN11960. Talaromyces emersonii: 051200J9, 051200J10, 051200J11 , 051200J12, 051200J13,
051200J14, 051200J15 and 051200J16 (SEQ ID NO: 19-26), thus creating pENI2159, when cloned into pENH 960.
Thermomyces ibadanensis: 051200J17, 051200J18, 051200J19, 051200J20, 051200J21 , 051200J22, 051200J23 and 051200J24 (SEQ ID NO: 27-34), thus creating pENI2160, when cloned into pENI1960.
Talaromyces byssochlamydoides: 080201 P1 , 080201 P2, 080201 P3, 080201 P4, 080201 P5, 080201 P6, 080201 P7 and 080201 P8 (SEQ ID NO: 54-61), thus creating pENI2230 when cloned into pENI1960.
Example 7: Shuffling of the intron-less lipase genes A method using dUTP and uracil-DNA glycosylase was employed in order to make
DNA fragments in sufficient quantities for DNA shuffling. The 3 genes 7. lanuginosus, 7 .thermophilus and 7.ibadanensis are quite homologous to each other (thus named Group A) as are 7. emersonii and 7. byssochlamydoides (named Group B). Thus in order to improve recombination between the two groups the following PCR scheme (see Fig. 1) was employed,
using the following templates: pENI2178, pENI2159, pENI2160, pENI2230, and the 7. lanuginosus gene cloned into pENI1902 (cut BamHI and Sacll) (pat. PCT/DK02/00050).
The following oligonucleotides are shown in Fig. 1 : 1298-taka, 19670, 19672, 115120 and 050401 P6 (SEQ ID NO: 62-65 and 68). 050401 P1 (SEQ ID NO: 66) hybridises to 5' 7 la- 5 nuginose lipase gene. 030501 P1 (SEQ ID NO: 67) hybridises to 5' of the other 4 lipase genes.
The final PCR fragment was cut first with BstEII and then with Sfil, as was the vector pENI2376. pENI2376 is a derivative of pENI1861(pat. PCT/DK02/00050)
The vector and PCR-fragment was purified from a 1 % gel and ligated O/N. The ligated DNA pool was transformed into electro-competent E.coli DH10B, thus creating a library 10 of app. 700.000 independent clones.
This library can be screened for activity towards various substrates such as Lecithin, DGDG, triglycerides such as tributyrine, olive oil, PNP-valerate or PNP-palmitate at different conditions such as high pH, low pH, high temperature, in presences of detergent, in the presence of ions or in the absence of ions. 15 This can be done in order to find, e.g., a thermo-stable lipase, a detergent phospholipase, a detergent lipase with first-wash performance, and no activity at neutral pH and so forth.
DNA- oligoes:
20 1298-taka: gcaagcgcgcgcaatacatggtgttttgatcat
19670: ccccatcctttaactatagcg 25
19672: ccacacttctcttccttcctc
115120: 30 gctttgtgcagggtaaatc
050401 P1 : cggccgggccgcggaggccagggatccaccatgaggagctcccttgtgctg
030501 P1 : cggccgggccgcggaggccacaagtttgtacaaaaaagcagg (hybridises to 5' of the other 4 lipase genes)
050401 P6: cggccgggtcaccccccatcctttaactatagcg
Example 8: Characterization of lipolytic enzymes
Lipolytic enzymes from Thermomyces ibadanensis and Talaromyces thermophilus were prepared as described above, purified and used for characterization
The specific lipase activity was determined by the LU method described in WO 0032758, and the amount of enzyme protein was determined from the optical density at 280 nm. The specific activity was found to be 3181 LU/mg for the Th. ibadanensis lipase and 1000 LU/mg for the 7a/. thermophilus lipase.
The pH-activity relation was found by determining the lipase by the LU method at pH
5, 6, 7, 8, 9 and 10. Both enzymes were found to have the highest lipase activity at pH 10. The
Th. ibadanensis lipase showed a broad optimum with more than 50 % of maximum activity in the pH range 6-10 whereas the 7a/. thermophilus lipase showed a stronger activity drop at lower pH with less than 30 % of maximum activity at pH 5-8.
The thermostability was determined by differential scanning calorimetry (DSC) at pH 5 (50 mM acetate buffer), pH 7 (50 mM HEPES buffer) and pH 10 (50 mM glycine buffer) with a scan rate of 90°C/hr. The temperature at the top of the denaturation peak (Td) was found to be as follows:
Example 9: Lysophospholipase activity
Purified lipolytic enzymes from 7 ibadanensis and 7. thermos were tested by incubating with lysolecithin as substrate at pH 5 and 7, and the extent of reaction was followed by use of NEFA kit. The results were that the enzyme from 7. ibadanensis showed high lysophospholipase activity at pH 5 and some activity at pH 7. The enzyme from 7. thermos showed a slight activity.
The indications made below relate to the deposited microorganistn(s) or other biological material referred to in the description on: -1 page 4 -2 line 11-16 -3 Identification of Deposit -3-1 Name of depositary institution DSMZ-Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH -3-2 Address of depositary institution Mascheroder Weg lb , D-38124
Braunschweig , Germany -3-3 Date of deposit 08 February 2001 (08 . 02 .2001). -3-4 Accession Number DSMZ 14049 -4 Additional Indications NONE -5 Designated States for Which all designated States Indications are Made -6 Separate Furnishing of Indications NONE
These indications will be submitted to the International Bureau later
The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on: -1 page 4 -2 line 11-16 -3 Identification of Deposit -3-1 Name of depositary institution DSMZ-Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH -3-2 Address of depositary institution Mascheroder Weg lb , D-38124
Braunschweig , Germany -3-3 Date of deposit 08 February 2001 (08 . 02 . 2001) -3-4 Accession Number DSMZ 14051 -4 Additional Indications NONE -5 Designated States for Which all designated States Indications are Made -6 Separate Furnishing of Indications NONE
These indications will be submitted to the International Bureau later
FOR RECEIVING OFFICE USE ONLY -4 This form was received with the international application:
(yes or no) -4-1 Authorized officer
FOR INTERNATIONAL BUREAU USE ONLY -5 This form was received by the international Bureau on:
-1 Form - PCT/R0/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis) -1-1 Prepared using PCT-EASY Version 2 . 92 (updated 01 . 01 .2002) -2 International Application No.
-3 Applicant's or agent's file reference 10130-WO
The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on: -1 page 4 -2 line 11-16 -3 Identification of Deposit -3-1 Name of depositary institution DSMZ-Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH -3-2 Address of depositary institution Mascheroder Weg lb , D-38124
Braunschweig , Germany -3-3 Date of deposit 08 February 2001 (08 . 02 . 2001) -3-4 Accession Number DSMZ 14047 -4 Additional Indications NONE -5 Designated States for Which all designated States Indications are Made -6 Separate Furnishing of Indications NONE
These indications will be submitted to the International Bureau later
The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on: -1 page 4 -2 line 11-16 -3 Identification of Deposit -3-1 Name of depositary institution DSMZ-Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH -3-2 Address of depositary institution Mascheroder Weg lb , D-38124
Braunschweig , Germany -3-3 Date of deposit 08 February 2001 (08 . 02 .2001 ) -3-4 Accession Number DSMZ 14048 -4 Additional Indications NONE -5 Designated States for Which all designated States Indications are Made -6 Separate Furnishing of Indications NONE
These indications will be submitted to the International Bureau later
Claims
1. A method of producing a lipolytic enzyme which comprises: a) shuffling at least two polynucleotides which comprise: i) a polynucleotide encoding a polypeptide which has lipolytic enzyme activity and has an amino acid sequence having at least 90 % identity with the mature peptide of SEQ ID NO: 2, and ii) a polynucleotide encoding a polypeptide which has lipolytic enzyme activity and has an amino acid sequence having 55-90 % identity with the mature peptide of SEQ ID NO: 2 b) expressing the shuffled polynucleotides to form recombinant polypeptides, c) screening the polypeptides to select a polypeptide having lipolytic enzyme activity, and d) producing the selected polypeptide.
2. The method of claim 1 wherein the amino acid sequence encoded by polynucleotide (ii) has at least 90 % identity to the mature part of SEQ ID NO: 4, 6, 8 oi O.
3. The method of claim 1 or 2 wherein the polynucleotides comprise a polynucleotide having a nucleotide sequence having at least 90 % identity to the mature part of SEQ ID NO: 1 ,
3, 5, 7 or 9.
4. A polynucleotide which comprises a nucleotide sequence which encodes a lipolytic enzyme and which: a) is a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048, 14049, or 14051 , or b) is the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9 or can be derived therefrom by substitution, deletion, and/or insertion of one or more nucleo- tides, or c) has at least 90 % identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, at least 80 % identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 5, at least 65 % identity with the DNA sequence encoding a mature peptide shown in SEQ ID NO: 7 or at least 60 % identity with the DNA sequence encoding a ma- ture peptide shown in SEQ ID NO: 9, or d) is an allelic variant of the DNA sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9; or e) hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
5. The polynucleotide of claim 4 which further comprises one or more control sequences which are operably linked to said nucleotide sequence and capable of directing the expression of the lipolytic enzyme in a suitable expression host.
6. A recombinant expression vector comprising the polynucleotide of claim 5, a promoter, and transcriptional and translational stop signals.
7. A recombinant host cell transformed with the polynucleotide of claim 5 or the vector of claim 6.
8. A method for producing a polypeptide having lipolytic enzyme activity comprising cultivating the host cell of claim 7 under conditions conducive to production of the polypeptide, and recovering the polypeptide.
9. A polypeptide which has lipolytic enzyme activity and which: f) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047 or 14049, or g) has an amino acid sequence which is the mature peptide of SEQ ID NO: 6 or10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or h) has an amino acid sequence which has at least 80 % identity with the mature peptide of SEQ ID NO: 6 or at least 60 % identity with the mature peptide of SEQ ID NO: 10, or i) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 6 or 10 in purified form, or j) is an allelic variant of the mature peptide of SEQ ID NO: 6 or10; or k) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 5 or 9, or a subsequence thereof having at least 100 nucleotides.
10. The polypeptide of claim 9 which is native to a strain of Talaromyces or Thermomyces, particularly Thermomyces ibadanensis or Talaromyces byssochlamydoides.
11. A nucleic acid sequence comprising a nucleic acid sequence which encodes the polypeptide of claim 9 or 10.
12. A process for hydrolyzing the fatty acyl group in a lysophospholipid, comprising treating the lysophospholipid with a polypeptide which has lysophospholipase activity and which:
5 a) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048, 14049 or 14051 , or b) has an amino acid sequence which is the mature peptide of SEQ ID NO: 4, 6, 8 or10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or 10 c) has an amino acid sequence which has at least 55 % identity with the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or d) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 4, 6, 8 or 10 in purified form, or e) is an allelic variant of the mature peptide of SEQ ID NO: 4, 6, 8 or 10; or
15 f) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
13. A process according to claim 12 for improving the filterability of an aqueous solution or slurry of carbohydrate origin which contains lysophospholipid.
20 14. The process of the preceding claim wherein the solution or slurry contains a starch hydrolysate, particularly a wheat starch hydrolysate.
15. A detergent composition comprising a surfactant and a polypeptide which has lipolytic enzyme activity and which: a) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli 25 deposit number DSM 14047, 14048, 14049 or 14051 , or b) has an amino acid sequence which is the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or c) has an amino acid sequence which has at least 55 % identity with the mature pep- 30 tide of SEQ ID NO: 4, 6, 8 or 10, or d) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 4, 6, 8 or 10 in purified form, or e) is an allelic variant of the mature peptide of SEQ ID NO: 4, 6, 8 or10; or f) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
16. A flour composition comprising flour and a polypeptide which has lipolytic enzyme ac- tivity and which: a) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048, 14049 or 14051 , or b) has an amino acid sequence which is the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or c) has an amino acid sequence which has at least 55 % identity with the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or d) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 4, 6, 8 or 10 in purified form, or e) is an allelic variant of the mature peptide of SEQ ID NO: 4, 6, 8 or 10; or f) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
17. A process for producing a dough or a baked product made from dough, comprising adding to the dough a polypeptide which has lipolytic enzyme activity and which: g) is encoded by a DNA sequence cloned into a plasmid present in Escherichia coli deposit number DSM 14047, 14048, 14049 or 14051 , or h) has an amino acid sequence which is the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or can be derived therefrom by substitution, deletion, and/or insertion of one or more amino acids, or i) has an amino acid sequence which has at least 55 % identity with the mature peptide of SEQ ID NO: 4, 6, 8 or 10, or j) is immunologically reactive with an antibody raised against the mature peptide of SEQ ID NO: 4, 6, 8 or 10 in purified form, or k) is an allelic variant of the mature peptide of SEQ ID NO: 4, 6, 8 or 10; or
I) is encoded by a nucleic acid sequence which hybridizes under high stringency conditions with a complementary strand of the nucleic acid sequence encoding a mature peptide shown in SEQ ID NO: 3, 5, 7 or 9, or a subsequence thereof having at least 100 nucleotides.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100304 | 2001-02-23 | ||
| DKPA200100304 | 2001-02-23 | ||
| PCT/DK2002/000124 WO2002066622A2 (en) | 2001-02-23 | 2002-02-25 | Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002234513A1 true AU2002234513A1 (en) | 2003-02-27 |
| AU2002234513B2 AU2002234513B2 (en) | 2006-12-07 |
Family
ID=8160293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002234513A Ceased AU2002234513B2 (en) | 2001-02-23 | 2002-02-25 | Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040101928A1 (en) |
| EP (1) | EP1404827A2 (en) |
| JP (2) | JP2004522448A (en) |
| CN (1) | CN1526013A (en) |
| AU (1) | AU2002234513B2 (en) |
| CA (1) | CA2432375C (en) |
| WO (1) | WO2002066622A2 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745599B1 (en) | 1995-06-07 | 2010-06-29 | Danisco A/S | Hexose oxidase-encoding DNAs and methods of use thereof |
| US6358543B1 (en) | 1995-06-07 | 2002-03-19 | Danisco A/S | Method of improving the properties of a flour dough, a flour dough improving composition and improved food products |
| US6936289B2 (en) | 1995-06-07 | 2005-08-30 | Danisco A/S | Method of improving the properties of a flour dough, a flour dough improving composition and improved food products |
| US8178090B2 (en) | 1995-06-07 | 2012-05-15 | Danisco A/S | Recombinant hexose oxidase |
| GB0112226D0 (en) | 2001-05-18 | 2001-07-11 | Danisco | Method of improving dough and bread quality |
| CO4520252A1 (en) | 1995-06-07 | 1997-10-15 | Bioteknologisk Inst | RECOMBINANT HEXOSE OXIDASE |
| ES2168236T3 (en) | 1997-04-09 | 2005-04-16 | Danisco A/S | USE OF LIPASE TO IMPROVE BREAD PASTA AND BAKERY PRODUCTS. |
| DK1387616T3 (en) | 2001-05-18 | 2007-09-24 | Danisco | Process for preparing a dough with an enzyme |
| EP1803353A3 (en) * | 2001-05-18 | 2007-07-18 | Danisco A/S | Method of preparing a dough with an enzyme |
| AU2003266941A1 (en) | 2002-10-01 | 2004-04-23 | Novozymes A/S | Family gh 61 polypeptides |
| DE602004030000D1 (en) | 2003-01-17 | 2010-12-23 | Danisco | PROCESS FOR IN-SITU-PRODUCTION OF AN EMULSIFIER IN A FOODSTUFF |
| EP1675941B1 (en) | 2003-06-25 | 2013-05-22 | Novozymes A/S | Polypeptides having alpha-amylase activity and polynucleotides encoding same |
| GB0405637D0 (en) | 2004-03-12 | 2004-04-21 | Danisco | Protein |
| DK1776455T3 (en) | 2004-07-16 | 2015-06-22 | Dupont Nutrition Biosci Aps | LIPOLYTIC ENZYM, APPLICATIONS THEREOF IN THE FOOD INDUSTRY |
| EP1926753B1 (en) | 2004-12-22 | 2010-11-24 | Novozymes A/S | Hybrid enzymes consisting of an endo-amylase first amino acid sequence and a carbohydrate-binding module as second amino acid sequence |
| US20080138856A1 (en) * | 2005-02-10 | 2008-06-12 | Novozymes A/S | Enzymatic Enantioselective Ester or Amide Hydrolysis or Synthesis |
| DK2059590T3 (en) | 2006-07-14 | 2015-02-23 | Novozymes Inc | Methods for preparation of secreted polypeptides having biological activity |
| US7781200B2 (en) | 2006-07-14 | 2010-08-24 | Novozymes A/S | Polypeptides having lipase activity and polynucleotides encoding same |
| DE102006046719A1 (en) | 2006-10-02 | 2008-04-03 | Ab Enzymes Gmbh | DNA sequence coding for an Aspergillus fumigatus phospholipase, e.g. useful for desliming vegetable oil |
| DE102006046857A1 (en) | 2006-10-02 | 2008-04-03 | Ab Enzymes Gmbh | DNA sequence coding for an Aspergillus fumigatus lysophospholipase, e.g. useful for improving the filtration of sugar syrups |
| US8956853B2 (en) * | 2007-01-30 | 2015-02-17 | Bunge Oils, Inc. | Enzymatic degumming utilizing a mixture of PLA and PLC phospholipases |
| US8460905B2 (en) * | 2007-09-11 | 2013-06-11 | Bunge Oils, Inc. | Enzymatic degumming utilizing a mixture of PLA and PLC phospholipases with reduced reaction time |
| CN101646761B (en) | 2007-04-09 | 2013-05-08 | 诺维信公司 | An enzymatic treatment of skin and hide degreasing |
| US8241876B2 (en) | 2008-01-07 | 2012-08-14 | Bunge Oils, Inc. | Generation of triacylglycerols from gums |
| BR112012018822A2 (en) | 2009-12-21 | 2019-09-24 | Danisco Us Inc | surfactants that optimize the cleaning of lipase-treated lipase-treated stains |
| US8765425B2 (en) | 2011-03-23 | 2014-07-01 | Butamax Advanced Biofuels Llc | In situ expression of lipase for enzymatic production of alcohol esters during fermentation |
| US8759044B2 (en) | 2011-03-23 | 2014-06-24 | Butamax Advanced Biofuels Llc | In situ expression of lipase for enzymatic production of alcohol esters during fermentation |
| JP6216495B2 (en) * | 2011-04-19 | 2017-10-18 | 三菱ケミカルフーズ株式会社 | Production method of puffed food |
| US10165709B2 (en) * | 2016-05-11 | 2018-12-25 | Facebook, Inc. | Modular network switches, associated structures, and associated methods of manufacture and use |
| EA201991443A1 (en) * | 2016-12-14 | 2020-01-14 | Вагенинген Университейт | THERMAL STABLE NUCLEASES Cas9 |
| CN106676084B (en) * | 2017-02-09 | 2019-11-29 | 浙江工业大学 | A kind of lipase mutant, encoding gene and its application from thermophilic ankle section bacterium |
| CN112175967B (en) * | 2020-10-10 | 2021-10-29 | 安徽农业大学 | A PEN1 gene that enhances plant resistance to lepidopteran pests and its application |
| CN112175976B (en) * | 2020-11-12 | 2021-12-28 | 武汉轻工大学 | A high temperature resistant lipase gene tllgold and its application |
| EP4397754A4 (en) * | 2021-08-30 | 2025-08-20 | Amano Enzyme Inc | ENZYMATIC TRANSESTERIFICATION AGENT WITH LIPASE AS ACTIVE INGREDIENT |
| US20250270600A1 (en) | 2022-04-20 | 2025-08-28 | Novozymes A/S | Process for producing free fatty acids |
| AU2023272468A1 (en) | 2022-05-14 | 2024-11-14 | Novonesis Plant Biosolutions A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5584397A (en) * | 1978-12-20 | 1980-06-25 | Ajinomoto Kk | Fat and oil ester exchange using lipase |
| EP0258068B1 (en) | 1986-08-29 | 1994-08-31 | Novo Nordisk A/S | Enzymatic detergent additive |
| US5869438A (en) * | 1990-09-13 | 1999-02-09 | Novo Nordisk A/S | Lipase variants |
| DE69226636T2 (en) * | 1991-05-01 | 1999-05-06 | Novo Nordisk A/S, Bagsvaerd | STABILIZED ENZYMS |
| DK0575133T4 (en) | 1992-06-16 | 2008-10-20 | Sankyo Lifetech Company Ltd | Hitherto known Phospholipase A1, process for its preparation and its use |
| ATE222604T1 (en) * | 1994-02-22 | 2002-09-15 | Novozymes As | METHOD FOR PRODUCING A VARIANT OF A LIPOLYTIC ENZYME |
| CN1193346A (en) | 1995-07-14 | 1998-09-16 | 诺沃挪第克公司 | A modified enzyme with lipolytic activity |
| DK0843725T3 (en) * | 1995-08-11 | 2002-08-12 | Novozymes As | Procedure for Preparation of Polypeptide Variants |
| DE19701348A1 (en) | 1997-01-16 | 1998-07-23 | Roehm Gmbh | Protein with phospholipase activity |
| US6159687A (en) * | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods for generating recombined polynucleotides |
| WO1998041622A1 (en) * | 1997-03-18 | 1998-09-24 | Novo Nordisk A/S | Method for constructing a library using dna shuffling |
| ES2168236T3 (en) | 1997-04-09 | 2005-04-16 | Danisco A/S | USE OF LIPASE TO IMPROVE BREAD PASTA AND BAKERY PRODUCTS. |
| DK1131416T3 (en) * | 1998-11-27 | 2009-10-26 | Novozymes As | Lipolytic Enzyme Variants |
| DE60233782D1 (en) * | 2001-02-07 | 2009-11-05 | Novozymes As | lipase |
-
2002
- 2002-02-25 AU AU2002234513A patent/AU2002234513B2/en not_active Ceased
- 2002-02-25 WO PCT/DK2002/000124 patent/WO2002066622A2/en not_active Ceased
- 2002-02-25 CA CA2432375A patent/CA2432375C/en not_active Expired - Fee Related
- 2002-02-25 JP JP2002566329A patent/JP2004522448A/en not_active Withdrawn
- 2002-02-25 EP EP02701241A patent/EP1404827A2/en not_active Withdrawn
- 2002-02-25 CN CNA028054725A patent/CN1526013A/en active Pending
- 2002-02-25 US US10/250,824 patent/US20040101928A1/en not_active Abandoned
-
2006
- 2006-06-23 US US11/474,151 patent/US7271139B2/en not_active Expired - Fee Related
-
2007
- 2007-08-28 JP JP2007221636A patent/JP4130693B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002234513B2 (en) | Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes | |
| AU2002234513A1 (en) | Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes | |
| EP2119773A1 (en) | Lipolytic enzymes from strains of fusarium and acremonium | |
| US7226770B2 (en) | Lipolytic enzyme variant | |
| EP1360278B1 (en) | Lipase variants | |
| US7172997B2 (en) | Lipolytic enzyme variant | |
| DK2044188T3 (en) | Polypeptides with lipase activity and polynucleotides encoding them | |
| US6506588B2 (en) | Lipolytic enzymes | |
| HUT71315A (en) | Modified cutinases, dna, vector and host | |
| US6511837B2 (en) | Lipolytic enzymes | |
| HUT74267A (en) | Detergent compositions containing enzime | |
| US6645749B2 (en) | Lipolytic enzyme | |
| EP0851913A1 (en) | Novel lipolytic enzymes | |
| US6509182B2 (en) | Lipolytic enzymes | |
| AU2002219020A1 (en) | Thermostable lipolytic enzyme variant | |
| CA2150837A1 (en) | Modified cutinases, dna, vector and host | |
| WO2002024881A1 (en) | Phospholipase from zygoascus hellenicus | |
| US20040152180A1 (en) | Lipolytic enzyme variant | |
| CA2334041A1 (en) | Enzyme with xylanase activity |